Search

everythinglearnresearchcommunity

for

Search:↓

Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.

Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Alfatradiol is suggested as another potential solution.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.

The user has been using dutasteride, minoxidil, and RU58841 for a year to stabilize hair loss and is considering a hair transplant. They are taking 5mg of oral minoxidil daily and are unsure of its effectiveness but have noticed more hair than a year ago.

The user shared their hair loss treatment progress using topical products like exosomes, fluridil, Kx826, and topical dutasteride, avoiding oral finasteride and dutasteride due to side effects. They found exosomes from Creative Biolabs most effective and also used topical probiotics, noting improvements without significant side effects.

Alfatradiol (0.025%) is an effective and safe treatment for androgenetic alopecia in both men and women, increasing anagen hair rates with minimal side effects. Users discuss its cost-effectiveness and ease of use compared to other treatments like finasteride and RU58841, with some combining it with stemoxydine and Minoxidil.

A user shared progress pictures showing significant hair growth after taking oral finasteride and oral minoxidil for 30 days. Other users expressed disbelief at the rapid results, with some attributing changes to camera effects.

Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

The user has been using a daily capsule containing 1mg finasteride and 2.5mg minoxidil for 11 months, with noticeable regrowth on the crown but minimal improvement on the hairline. They experienced no significant side effects and plan to continue the treatment long-term.

Dutasteride may cause chronic infertility by reducing semen volume and motility, with concerns about irreversible prostate fibrosis. Users consider switching to finasteride or using treatments like minoxidil and microneedling, weighing hair preservation against fertility.

Rice water was used as a hair treatment and showed noticeable results in a week, more than finasteride used for seven months. The user plans to continue using rice water and might stop finasteride, while still using ketoconazole for dandruff.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.

A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The conversation discusses a new study on topical pumpkin seed oil for hair loss in mice. Treatments mentioned include Minoxidil, finasteride, and RU58841.

Minoxidil is highly toxic to pets, and there is a call for manufacturers to add a "Toxic to Pets" warning on packaging. A petition has been started to raise awareness and prevent pet fatalities.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

The conversation is about the potential format of Breezula, a hair loss treatment, and concerns that it might be greasy or sticky. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.

The conversation discusses the potential effects of spearmint on acne and male pattern baldness (MPB). Concerns are raised about spearmint's androgen-suppressing effects and its suitability for men.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

The conversation discusses treatments for Androgenetic Alopecia, including Minoxidil, finasteride, RU58841, and topical caffeine. It emphasizes that there are multiple treatment options available in 2025.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

A transwoman is struggling with hair loss despite using hormones, dutasteride, and Abiraterone, and is considering making her own treatments due to difficulty accessing them. She has also tried Eucapil and regularly uses Nizoral shampoo.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

The user is experiencing erectile dysfunction and decreased sperm quality from using Dutasteride for hair loss and is considering stopping it to improve fertility. They are exploring other treatments like Viviscal Men, Minoxidil, Revlan Red System, Fluridil, Nizoral, Stemoxydine, and Eucapil.